Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
WEDNESDAY, APRIL 29, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
GLOBAL PREVENTION OF DIABETES
Madhu Malo
Stapgen LLC

Madhu Malo

Stapgen LLC

  • Linking diabetes risk to intestinal alkaline phosphatase deficiency and endotoxin detoxification
  • Reviewing mouse evidence that bovine IAP supplementation prevents hyperglycemia in diabetes models
  • Outlining how therapeutic-grade BIAP could be evaluated as a scalable diabetes-prevention approach
10:05 - 10:10
Q&A SESSION ON GLOBAL DIABETES PREVENTION
10:10 - 10:35
OPTIMIZING GLP-1 AGONIST THERAPY THROUGH METHYLATION PATHWAY ASSESSMENT
Charles Sailey
Molecular Testing Labs

Charles Sailey

Molecular Testing Labs

  • Introducing gene-guided GLP-1 optimization using methylation variants like MTHFR and COMT
  • Enhancing metabolic outcomes by correcting inefficiencies in one-carbon nutrient pathways
  • Demonstrating improved GLP-1 efficacy and detox response through precision supplementation
10:35 - 10:40
Q&A SESSION ON PRECISION GENETICS AND GLP-1 RESPONSE
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON THE SILENT EPIDEMIC OF METABOLIC SYNDROME
  • Uncovering barriers to early detection and prioritizing underestimated modern drivers to scale effective metabolic syndrome interventions
  • Clarifying pivotal causes, diagnosing diabetes vulnerability, and applying practical prevention steps to stop progression from metabolic syndrome
  • Reframing lifestyle design and coaching to overcome limits of medical advice and exercise for durable population scale reversal

| Lembas

| Stapgen LLC

| The Erring Human

11:30 - 11:55
TRANSFORMING OBESITY RESEARCH WITH METABOLIC TRACER TECHNOLOGIES
Tom Angel
Metabolic Solutions

Tom Angel

Metabolic Solutions

  • Tracking patient fat synthesis, oxidation and energy use directly with metabolic tracer assays
  • Using tracer-based case studies that add valuable endpoints in metabolic disease trials
  • Implementing tracer protocols into preclinical and clinical workflows without disrupting operations
  • Aligning tracer platforms with GLP standards and regulators to speed adoption in obesity research
11:55 - 12:00
Q&A SESSION ON METABOLIC TRACERS IN OBESITY RESEARCH
12:00 - 13:30
NETWORKING LUNCH AND VISITING THE OBESITY MEDICINE EXHIBITION
13:30 - 13:55
FINANCING AND CORPORATE TRANSACTIONS ENVIRONMENT IN METABOLIC MEDICINE: CURRENT TRENDS AND OUTLOOK FOR THE FUTURE
Stan Glezer
Outcome Capital, LLC

Stan Glezer

Outcome Capital, LLC

  • Assessing how 2025 financing headwinds slow early metabolic R&D and academic spin-out formation
  • Tracing the shift from late-stage deals to earlier licensing and partnering by major pharma groups
  • Anticipating global impacts as China and Asian biotechs challenge US and European deal dominance
13:55 - 14:00
Q&A SESSION ON FINANCING TRENDS IN METABOLIC MEDICINE
14:00 - 14:25
THE MIND/BODY PROBLEM – METABOLIC SYNDROME AND COGNITIVE DECLINE
Steve Winshel
Paraxis

Steve Winshel

Paraxis

  • Clarifying the strong links between metabolic dysfunction and cognitive impairments
  • Highlighting complications due to the late detection of cognitive decline in patients
  • Showcasing innovative early detection tools to slow or prevent brain changes
  • Integrating mind-body approaches to address both metabolic and cognitive issues
14:25 - 14:30
Q&A SESSION ON LINKING METABOLISM AND BRAIN HEALTH
14:30 - 14:55
DIGITAL INNOVATION IN METABOLIC PSYCHIATRY
Megan Kirk Chang
University of Oxford

Megan Kirk Chang

University of Oxford

  • Exploring staged metabolic care with ketogenic diets and GLP-1-supported lifestyle in psychiatry
  • Delivering AI-enabled ketogenic insights and lifestyle guidance with monitoring and real-world data
Noah Wayne
NexJ Health Inc.

Noah Wayne

NexJ Health Inc.

  • Prioritising key lifestyle components and evidence to embed digital metabolic care in psychiatry
  • Tailoring clinical workflows and research to integrate AI-enabled lifestyle platforms at scale
14:55 - 15:00
Q&A SESSION ON DIGITAL METABOLIC PSYCHIATRY IN PRACTICE
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
THE MIND-METABOLISM LOOP
Eric Headlee
Arise Elite Longevity

Eric Headlee

Arise Elite Longevity

  • Reconceptualising metabolic disease and longevity as homocysteine-centred signals of stress
  • Unpacking stress and glucose loops that raise homocysteine, damage vessels and brain
  • Clarifying genetic variants like MTHFR as stress-amplifying risks, not deterministic disease drivers
  • Structuring a resolution–regulation–optimisation path for early, system-level prevention
15:55 - 16:00
Q&A SESSION ON THE MIND–METABOLISM LOOP IN METABOLIC DISEASES
16:00 - 16:25
UNLOCKING NATURAL WEIGHT-REGULATING BIOLOGY THROUGH LEPTIN SENSITIZATION
Teo Uysal
ERX Pharmaceuticals

Teo Uysal

ERX Pharmaceuticals

  • Delving into leptin's pivotal role in weight regulation and obesity treatment
  • Uncovering unique biological mechanisms for enhanced efficacy and muscle preservation
  • Presenting promising initial findings from a Phase 1 study of a novel leptin sensitizer
16:25 - 16:30
Q&A SESSION ON LEPTIN SENSITIZATION IN OBESITY TREATMENT
16:30 - 16:55
ENABLING DEVICE SOLUTIONS FOR UNMET NEEDS IN BIOTHERAPIES
Asmita Khanolkar
SMC® Ltd.

Asmita Khanolkar

SMC® Ltd.

  • Highlighting novel methods for drug-device-delivery optimization and assessment
  • Introducing an autoinjector simulator to evaluate pharmacokinetics and dynamics
  • Accelerating early evaluation and speed to clinics for biologics with unique needs
16:55 - 17:00
Q&A SESSION ON ENABLING DEVICE SOLUTIONS IN BIOTHERAPIES
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, APRIL 30, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
ENSURING ACCESS AND SUPPORT IN OBESITY CARE
Sansei Fowler
CVS Health

Sansei Fowler

CVS Health

  • Enhancing patient access to obesity treatments through optimal payer coverage strategies
  • Coordinating care models for GLP-1 therapy for comprehensive support to improved outcomes
  • Forecasting future trends in obesity treatment by analyzing drug pipelines and the role of PBMs in care
10:05 - 10:10
Q&A SESSION ON THE ACCESS AND SUPPORT IN OBESITY TREATMENT
10:10 - 10:35
NA-931: AN ORAL QUADRUPLE RECEPTOR AGONIST FOR WEIGHT LOSS WITHOUT MUSCLE LOSS
Lloyd Tran
Biomed Industries, Inc.

Lloyd Tran

Biomed Industries, Inc.

  • Describing the mechanism of action of this oral quadruple receptor agonist
  • Summarizing topline Phase 1 and Phase 2 clinical trial results on the safety and efficacy of NA-931
  • Reporting significant weight loss with no muscle loss or major GI-related adverse events
10:35 - 10:40
Q&A SESSION ON NA-931 AND ADVANCES IN WEIGHT MANAGEMENT
10:40 - 11:05
METABOLIC ARCHITECTURE: THE PHYSIOLOGY OF A HIGH-RETENTION CLINICAL ECOSYSTEM
Naomi Parrella
Classic Care MD

Naomi Parrella

Classic Care MD

  • Harmonizing pharmacotherapy, surgery and lifestyle in a metabolic loop that preserves lean mass
  • Standardizing care with the ABCDE framework so teams deliver consistent metabolic plans at scale
  • Achieving a solvent, high-reliability clinic model with >65% retention and employer-aligned growth
11:05 - 11:10
Q&A SESSION ON HIGH-RETENTION METABOLIC CARE MODELS
11:10 - 11:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:30 - 11:55
EXPLORING INNOVATIVE TECHNOLOGIES IN THE FIGHT AGAINST OBESITY
Ashley Zehnder
Fauna Bio

Ashley Zehnder

Fauna Bio

  • Discussing rising global obesity rates and the urgent need for innovative solutions
  • Examining the role of muscle-preserving agents in improving metabolic health during weight loss
  • Highlighting recent technological and biomedical advancements in obesity treatment strategies
11:55 - 12:00
Q&A SESSION ON USING MUSCLE PRESERVATION FOR OBESITY TREATMENTS
12:00 - 12:25
BRIDGING CLINICAL EFFICACY AND SCALABLE ENTERPRISE IMPLEMENTATION: EMED'S GLP-1 PROGRAM
Dyan Hes
eMed

Dyan Hes

eMed

  • Describing a digitally integrated, employer GLP-1 program with structured telehealth oversight
  • Orchestrating prescribing, titration, safety checks and at-home biomarker testing in obesity care
  • Visualising de-identified BMI, biomarker and engagement trends for employers on secure dashboards
12:25 - 12:30
Q&A SESSION ON SCALABLE GLP-1 CARE DELIVERY MODELS
12:30 - 12:55
FINDING THE RARE IN THE MASS: USING RWE TO IDENTIFY RARE METABOLIC PHENOTYPES IN THE GLP-1 ERA
Sanjay Ahuja
Regal Intel

Sanjay Ahuja

Regal Intel

  • Detecting GLP-1 non- and super-responders in RWE to uncover hidden rare metabolic phenotypes
  • Profiling claims and EHR histories to flag GLP-1 non-responders suitable for disease screening
  • Validating GLP-1 use in select rare conditions with RWE to support orphan indications and pricing
  • Constructing synthetic control arms from historical data to speed trials in rare indications
12:55 - 13:00
Q&A SESSION ON RWE FOR RARE METABOLIC PHENOTYPES
13:00 - 13:15
FEEDBACK & RAFFLE DRAW
13:15 - 14:30
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.